Cargando…

Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study

Objective To study the effectiveness and safety of the non-vitamin K antagonist oral anticoagulants (novel oral anticoagulants, NOACs) dabigatran, rivaroxaban, and apixaban compared with warfarin in anticoagulant naïve patients with atrial fibrillation. Design Observational nationwide cohort study....

Descripción completa

Detalles Bibliográficos
Autores principales:	Larsen, Torben Bjerregaard, Skjøth, Flemming, Nielsen, Peter Brønnum, Kjældgaard, Jette Nordstrøm, Lip, Gregory Y H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910696/ https://www.ncbi.nlm.nih.gov/pubmed/27312796 http://dx.doi.org/10.1136/bmj.i3189

Ejemplares similares

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
por: Nielsen, Peter Brønnum, et al.
Publicado: (2017)

Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity‐Weighted Cohort Study
por: Søgaard, Mette, et al.
Publicado: (2019)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage
por: Nielsen, Peter Brønnum, et al.
Publicado: (2019)

Bleeding Complications in Anticoagulated Patients With Atrial Fibrillation and Sepsis: A Propensity‐Weighted Cohort Study
por: Søgaard, Mette, et al.
Publicado: (2017)

Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
por: Søgaard, Mette, et al.
Publicado: (2019)

Atrial fibrillation in patients with severe mental disorders and the risk of stroke, fatal thromboembolic events and bleeding: a nationwide cohort study
por: Søgaard, Mette, et al.
Publicado: (2017)

Hematuria in anticoagulated patients with atrial fibrillation and urologic cancer
por: Ording, Anne Gulbech, et al.
Publicado: (2022)

Effectiveness and safety of self-managed oral anticoagulant therapy compared with direct oral anticoagulants in patients with atrial fibrillation
por: Grove, Erik Lerkevang, et al.
Publicado: (2018)

Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study
por: Nielsen, Peter Brønnum, et al.
Publicado: (2016)

Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants
por: Ording, Anne Gulbech, et al.
Publicado: (2021)

Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Venous Thromboembolism in Cancer Patients: A Semi Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes
por: Larsen, Torben Bjerregaard, et al.
Publicado: (2014)

Disparities in oral anticoagulation initiation in patients with schizophrenia and atrial fibrillation: A nationwide cohort study
por: Højen, Anette Arbjerg, et al.
Publicado: (2022)

Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis
por: Rasmussen, Lars Hvilsted, et al.
Publicado: (2012)

Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation and Aortic Stenosis
por: Melgaard, Line, et al.
Publicado: (2021)

Cost Effectiveness of Patient Self-Managed Warfarin Compared with Direct Oral Anticoagulants in Atrial Fibrillation: An Economic Evaluation in a Danish Healthcare Sector Setting
por: Raunbak, Sabine Michelsen, et al.
Publicado: (2022)

The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis
por: Vestergaard, Anne Sig, et al.
Publicado: (2017)

Risk of Cerebrovascular Events in Intracerebral Hemorrhage Survivors With Atrial Fibrillation: A Nationwide Cohort Study
por: Nielsen, Peter Brønnum, et al.
Publicado: (2022)

Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy
por: Søgaard, Mette, et al.
Publicado: (2022)

Sex Differences in Treatment Quality of Self-Managed Oral Anticoagulant Therapy: 6,900 Patient-Years of Follow-Up
por: Nilsson, Hanna, et al.
Publicado: (2014)

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients without previous oral anticoagulants or stable under warfarin: a nationwide cohort study
por: Liu, Shin-Huei, et al.
Publicado: (2023)

Risk of stroke or systemic embolism in patients with degenerative mitral stenosis with or without atrial fibrillation: A cohort study
por: Steiner, Daniel Kjærgaard, et al.
Publicado: (2022)

Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care
por: Lane, Deirdre A., et al.
Publicado: (2017)

Hospital admission and mortality rates for non-covid diseases in Denmark during covid-19 pandemic: nationwide population based cohort study
por: Bodilsen, Jacob, et al.
Publicado: (2021)

Evaluation of Risk Scores as Predictive Tools for Stroke in Patients with Retinal Artery Occlusion: A Danish Nationwide Cohort Study
por: Ørskov, Marie, et al.
Publicado: (2022)

Risk of stroke and bleeding in patients with heart failure and chronic kidney disease: a nationwide cohort study
por: Melgaard, Line, et al.
Publicado: (2018)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation
por: Friberg, Leif, et al.
Publicado: (2017)

Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin
Publicado: (2020)

Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin
por: Huang, Huei‐Kai, et al.
Publicado: (2020)

Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry
por: Liang, Hai-Feng, et al.
Publicado: (2019)

Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
por: Lee, Hsin‐Fu, et al.
Publicado: (2019)

Ten years of non-vitamin K antagonists oral anticoagulants for stroke prevention in atrial fibrillation: is warfarin obsolete?
por: Hammwöhner, Matthias, et al.
Publicado: (2020)

Cardiovascular and renal protective effects of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation
por: Choi, Seong Huan, et al.
Publicado: (2022)

Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study
por: Lip, Gregory Y H, et al.
Publicado: (2012)

Impact of Reduced-Dose Nonvitamin K Antagonist Oral Anticoagulants on Outcomes Compared to Warfarin in Korean Patients with Atrial Fibrillation: A Nationwide Population-Based Study
por: Han, Sola, et al.
Publicado: (2021)

Real-world comparison of non-vitamin K antagonist oral anticoagulants and warfarin in Asian octogenarian patients with atrial fibrillation
por: Kwon, Chang Hee, et al.
Publicado: (2016)

Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
por: de Padua Mansur, Antonio, et al.
Publicado: (2012)

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
por: Choi, Jiyoon C, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2en3ar7vha40famj0ulnm8k60v